/ITOS

ITOS Stock - iTeos Therapeutics, Inc.

Q: What is the analyst price target for ITOS?

Analyst price target information is not currently available for ITOS.

Q: What is ITOS's market cap?

Market capitalization information is not currently available for ITOS.

Healthcare|Biotechnology|NASDAQ

$10.15+0.20%

+$0.02 (+0.20%) • Aug 29

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+23.2%upside

Target: $12.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ITOS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.49

52W High$17.63

52W Low$4.80

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$35.00M	$12.60M	$267.63M	$344.77M	N/A
Gross Profit	$33.76M	$11.70M	$266.82M	$344.16M	$-535,000
Gross Margin	96.5%	92.9%	99.7%	99.8%	N/A
Operating Income	$-159,528,000	$-151,101,000	$126.32M	$244.90M	$-45,240,000
Net Income	$-134,414,000	$-112,642,000	$96.65M	$214.52M	$-38,033,000
Net Margin	-384.0%	-894.3%	36.1%	62.2%	N/A
EPS	$-3.32	$-3.15	$2.72	$6.10	$-1.24

Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish4 Neutral/Bearish

Price Targets

$16

Average Target

↑ 57.6% Upside

Now

Low

$16

Average

$31

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 28th 2025	Wells Fargo	Downgrade	Equal Weight	$12
May 28th 2025	Wedbush	Downgrade	Neutral	$12
May 14th 2025	Leerink Partners	Downgrade	Market Perform	$9
May 14th 2025	H.C. Wainwright	Downgrade	Neutral	-
May 13th 2025	JP Morgan	Downgrade	Neutral	-
August 13th 2024	Wells Fargo	Initiation	Overweight	$31

Earnings History & Surprises

ITOS

Beat Rate

60%

Last 20 quarters

Avg Surprise

+17.4%

EPS vs Estimate

Beats / Misses

12/8

Last 12 quarters

Latest EPS

$-1.51

Q3 2025

EPS Surprise History

Q4 23

+25.0%

$-0.90vs$-1.20

Q1 24

+17.5%

$-0.85vs$-1.03

Q2 24

-4.9%

$-1.07vs$-1.02

Q3 24

+82.7%

$-0.18vs$-1.04

Q4 24

+11.0%

$-1.05vs$-1.18

Q1 25

+11.4%

$-1.01vs$-1.14

Q2 25

+14.9%

$-0.80vs$-0.94

Q3 25

-34.8%

$-1.51vs$-1.12

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 6, 2025	$-1.12	$-1.51	-34.8%	✗ MISS
Q2 2025	Apr 28, 2025	$-0.94	$-0.80	+14.9%	✓ BEAT
Q1 2025	Mar 5, 2025	$-1.14	$-1.01	+11.4%	✓ BEAT
Q4 2024	Nov 12, 2024	$-1.18	$-1.05	+11.0%	✓ BEAT
Q3 2024	Aug 8, 2024	$-1.04	$-0.18	+82.7%	✓ BEAT
Q2 2024	May 10, 2024	$-1.02	$-1.07	-4.9%	✗ MISS
Q1 2024	Mar 6, 2024	$-1.03	$-0.85	+17.5%	✓ BEAT
Q4 2023	Nov 7, 2023	$-1.20	$-0.90	+25.0%	✓ BEAT
Q3 2023	Aug 8, 2023	$-1.03	$-0.96	+6.8%	✓ BEAT
Q2 2023	May 10, 2023	$-0.99	$-0.44	+55.6%	✓ BEAT
Q1 2023	Mar 15, 2023	$0.33	$0.57	+72.7%	✓ BEAT
Q4 2022	Nov 10, 2022	$0.10	$0.03	-70.0%	✗ MISS
Q3 2022	Aug 10, 2022	$1.20	$0.15	-87.5%	✗ MISS
Q2 2022	May 12, 2022	$0.80	$1.82	+127.5%	✓ BEAT
Q1 2022	Mar 23, 2022	$1.28	$4.89	+282.0%	✓ BEAT
Q4 2021	Nov 10, 2021	$4.95	$1.86	-62.4%	✗ MISS
Q3 2021	Aug 12, 2021	$-0.41	$-0.75	-82.9%	✗ MISS
Q2 2021	May 13, 2021	$-0.48	$-0.39	+18.7%	✓ BEAT
Q1 2021	Mar 24, 2021	$-0.42	$-0.43	-2.4%	✗ MISS
Q4 2020	Nov 12, 2020	$-0.36	$-0.48	-33.3%	✗ MISS

Frequently Asked Questions about ITOS

What is ITOS's current stock price?

iTeos Therapeutics, Inc. (ITOS) is currently trading at $10.15 per share. The stock has moved +0.20% today.

What is the analyst price target for ITOS?

The average analyst price target for ITOS is $12.50, based on 1 analyst.

What sector is iTeos Therapeutics, Inc. in?

iTeos Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ITOS's market cap?

iTeos Therapeutics, Inc. has a market capitalization of $0.45 billion, making it a small-cap company.

Does ITOS pay dividends?

No, iTeos Therapeutics, Inc. does not currently pay a dividend to shareholders.